These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 29154157)

  • 1. Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review.
    Lee Y; Rosenblat JD; Lee J; Carmona NE; Subramaniapillai M; Shekotikhina M; Mansur RB; Brietzke E; Lee JH; Ho RC; Yim SJ; McIntyre RS
    J Affect Disord; 2018 Feb; 227():406-415. PubMed ID: 29154157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.
    Khoo AL; Zhou HJ; Teng M; Lin L; Zhao YJ; Soh LB; Mok YM; Lim BP; Gwee KP
    CNS Drugs; 2015 Aug; 29(8):695-712. PubMed ID: 26293743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
    Kishi T; Ikuta T; Sakuma K; Okuya M; Hatano M; Matsuda Y; Iwata N
    Mol Psychiatry; 2023 Jan; 28(1):402-409. PubMed ID: 36253442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
    Cipriani A; Furukawa TA; Salanti G; Chaimani A; Atkinson LZ; Ogawa Y; Leucht S; Ruhe HG; Turner EH; Higgins JPT; Egger M; Takeshima N; Hayasaka Y; Imai H; Shinohara K; Tajika A; Ioannidis JPA; Geddes JR
    Lancet; 2018 Apr; 391(10128):1357-1366. PubMed ID: 29477251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.
    Tedeschini E; Levkovitz Y; Iovieno N; Ameral VE; Nelson JC; Papakostas GI
    J Clin Psychiatry; 2011 Dec; 72(12):1660-8. PubMed ID: 22244025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
    Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
    Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial and harmful effects of antidepressants versus placebo, 'active placebo', or no intervention for adults with major depressive disorder: a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses.
    Juul S; Siddiqui F; Barbateskovic M; Jørgensen CK; Hengartner MP; Kirsch I; Gluud C; Jakobsen JC
    Syst Rev; 2021 May; 10(1):154. PubMed ID: 34034811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
    Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A
    CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials.
    Soares CN; Kornstein SG; Thase ME; Jiang Q; Guico-Pabia CJ
    J Clin Psychiatry; 2009 Oct; 70(10):1365-71. PubMed ID: 19906341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
    Baune BT; Sluth LB; Olsen CK
    J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale.
    Hobart M; Zhang P; Weiss C; Meehan SR; Eriksson H
    Int J Neuropsychopharmacol; 2019 Mar; 22(3):173-179. PubMed ID: 30508090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning.
    Trivedi MH; Corey-Lisle PK; Guo Z; Lennox RD; Pikalov A; Kim E
    Int Clin Psychopharmacol; 2009 May; 24(3):133-8. PubMed ID: 19318972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of fatigue and energy on work functioning and impairment in patients with major depressive disorder treated with desvenlafaxine.
    Sarfati D; Evans VC; Tam EM; Woo C; Iverson GL; Yatham LN; Lam RW
    Int Clin Psychopharmacol; 2017 Nov; 32(6):343-349. PubMed ID: 28763344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies.
    Mancini M; Sheehan DV; Demyttenaere K; Amore M; Deberdt W; Quail D; Sagman D
    Int Clin Psychopharmacol; 2012 Nov; 27(6):298-309. PubMed ID: 22954893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
    Cipriani A; Zhou X; Del Giovane C; Hetrick SE; Qin B; Whittington C; Coghill D; Zhang Y; Hazell P; Leucht S; Cuijpers P; Pu J; Cohen D; Ravindran AV; Liu Y; Michael KD; Yang L; Liu L; Xie P
    Lancet; 2016 Aug; 388(10047):881-90. PubMed ID: 27289172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder.
    Lam RW; Iverson GL; Evans VC; Yatham LN; Stewart K; Tam EM; Axler A; Woo C
    J Affect Disord; 2016 Oct; 203():55-61. PubMed ID: 27280963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.